Sunday, June 22, 2014

What Price Antiviral Drugs? Sovaldi Hep-C Cure @$150 to $250 per person, sells @$84,000.

What Price Antiviral Drugs? Sovaldi Hep-C Cure @$150 to $250 per person, sells @$84,000.

...Gilead has agreed to help U.S. patients pay for Sovaldi if they cannot afford it, or help patients obtain drug coverage. The company also plans to charge substantially less for a course of treatment in India ($2000 for the 12 week course), Pakistan, Egypt ($990 for the 12 week course), and China, where most people infected with HCV live. These deals have prompted some to ask if the US is being forced to subsidize the cost of the drug worldwide. I personally do not object to helping other countries solve their HCV problem.

What is a fair price for a drug that can eliminate HCV infection? Gilead paid more than $11 billion in 2011 to acquire the company that developed Sovaldi, and it is reasonable for them to recoup that investment. Andrew Hill of the Department of Pharmacology and Therapeutics at Liverpool University estimates the manufacturing cost* of a 12 week course of treatment with this drug to be $150 to $250 per person. The answer to our fair price question must lie somewhere between these extremes. ...

Tuesday, June 17, 2014

#Liber8 #Gilead #Sovaldi : Sovaldi Cost to Manufacture $67, price $84,000.

AHF to Ask States to Block Gilead's $1,000 per Pill Hepatitis ...’s-100...
Business Wire
Jan 29, 2014 - At $1,000 per pill, Sovaldi price is 1,100% more than Gilead's AIDS drug ... price suggests a retail markup of 279,000% over production costs.

In his letter to state Medicaid directors, Weinstein wrote, “Gilead is charging a higher price for this drug even though the cost to produce it is small. According to industry reports, Gilead produces Sovaldi for approximately $1.00 per gram (with only 10 to 30 grams needed to successfully treat patients with Hepatitis C).1 This represents a retail markup of over 279,000%. (NOTE: With only 10 to 30 grams of Sovaldi needed for successful treatment, the difference from the $30 production cost for Gilead’s full course of treatment—30 grams x $1.00 per gram—to $84,000 for the 12-week treatment program represents a retail markup of 279,000%.)

The Sovaldi Tax: Gilead Can't Justify The Price It's Asking Americans ...

Forbes-5 hours ago
Sovaldi costs about $130 to manufacture, reinforcing how outrageous its pricing is. Gilead claims that the pricing reflects the value of Sovaldi ...
$1000-a-pill Sovaldi jolts US health care system
Bellingham Herald-12 minutes ago
Gilead Sciences, Inc. (NASDAQ:GILD) Drug Gets No Support From ...
WallStreetPR-5 hours ago

$1000-a-pill Sovaldi jolts US health care system

Sacramento Bee - ‎1 hour ago‎
Sovaldi, a new pill for hepatitis C, cures the liver-wasting disease in 9 of 10 patients, but treatment can cost more than $90,000. Leading medical societies recommend the drug as a first-line treatment, and patients are clamoring for it. But insurance companies ... 

1000 Pill For Hepatitis C Spurs Debate Over Drug Prices
Dec 30, 2013 - Gilead is making a new hepatitis C drug, Sovaldi. John Amis/AP Images for AIDS Healthcare Foundation. Timothy Webb and other advocates ...

New Hep C Drug Sovaldi Ignites Fierce Pricing Debate › Healthline News
Healthline Networks
Apr 11, 2014 - Sovaldi costs more than Olysio, which runs $66,360 for a 12-week ... manufacturers can set the cost to the target market, they can license ...

Drug costs and prices: Here we go again - Scientific American
Scientific American
Apr 24, 2014 - The $150 was the manufacturing cost, the $84,000 was the price. ... Sovaldi is also regarded as a first-in-class treatment for what was always ...

Gilead: Sovaldi Pricing Ethically And Economically Justified ...
Seeking Alpha
May 22, 2014 - Sovaldi's $84,000 price tag is a bargain compared to alternative drugs and ... So how could this little pill, that costs pennies to mass produce, ...

Gilead to license hepatitis C drug to lower-cost ... - Reuters
Feb 5, 2014 - Gilead to license hepatitis C drug to lower-cost manufacturers in India ... For example, the price discussed for 24 weeks of Sovaldi therapy ...

Sovaldi: Who's to Blame for the $1,000 a Day Cure ...

Wharton School of the University of Pennsylvania
Apr 16, 2014 - The eye-popping price tag for the hepatitis C drug Sovaldi has insurers ... “At that point, all you're talking about is the cost of manufacturing and ...
... More importantly, he says, the debate has overlooked one key aspect of the health care system that would have to be changed in order for the U.S. to take more control over drug pricing: the patent system. Sovaldi “is a patented drug. And patents exist because the government permits firms to make original discoveries and get a temporary monopoly on them,” Pauly notes. “The general idea is to allow companies to charge monopoly prices for a period of time to motivate innovation. That’s what Gilead is doing — they’re charging the monopoly price that is presumably based on what they think the market is willing to pay for their product.” ...

4 of the top 10 highest paid CEOs are in Medical Supplies or Drugs.

Hosea 6:8: 

"Gilead is a city of those who work iniquity; it is stained with blood."


 The Republican Healthcare Plan

 is the same as the Nazi Healthcare Plan for Old Jews...


#Liber8 #Gilead: The Sovaldi Tax: Gilead Can't Justify The Price It's Asking Americans To Pay

The Sovaldi Tax: Gilead Can't Justify The Price It's Asking Americans To Pay

A cure for hepatitis C is within reach for 170 million people around the world — thanks to the charitable efforts of poor and sick Americans who are picking up the tab by paying outrageous prices for their own treatment. It’s like Robin Hood in reverse.

This is what happens when a pill is priced at $1,000 a day in the U.S., and an entire treatment regimen of 84 of those pills costs just $900 in Egypt. Exact same medicine, completely different pricing. ...

... Sovaldi costs $84,000 for a course of treatment. Add in other therapies that supplement Sovaldi, and now you’re talking about $100,000 or so to treat a single patient. To use Sovaldi to treat each of the 3 million hepatitis C patients in the United States, it would cost around $300 billion, or about the same amount we annually spend for all other drugs combined. ...

... Sovaldi costs about $130 to manufacture, reinforcing how outrageous its pricing is. Gilead claims that the pricing reflects the value of Sovaldi and it deserves a premium because of downstream health savings. Following that logic, all antibiotics have been vastly underpriced since the introduction of penicillin some 60 years ago. ....

Sovaldi costs about $130 to manufacture,  says Forbes, ExpressScripts...

 Pot Kettle Black : John Martin $180,000,000.00 paycheck last year.

George Paz, ExpressScripts  $51,500,000.00 paycheck last year.

Hosea 6:8:  

"Gilead is a city of those who work iniquity; it is stained with blood."

Monday, June 16, 2014

#Liber8 #Gilead: NY extorted to pay $84,000 for drug that costs $67 to make.

NY grapples with cost of life-saving Hepatitis C drug

Capital New York - ‎9 hours ago‎
ALBANY—A new drug with a greater than 90-percent success rate for curing Hepatitis C is on the market, but the state may not be able to cover its cost for tens of thousands of people who don't have private insurance. Sovaldi, manufactured by Gilead ... 
ALBANY—A new drug with a greater than 90-percent success rate for curing Hepatitis C is on the market, but the state may not be able to cover its cost for tens of thousands of people who don't have private insurance.

Sovaldi, manufactured by Gilead Sciences, was approved by the federal Food and Drug Administration in December 2013. It costs $1,000 per pill, and a 12-week standard course of treatment—one pill a day—costs $84,000.

Many of those who would be treated with the drug won’t be covered by private insurance. More than half the estimated 3.2 million people infected with Hepatitis C nationwide—including prisoners, veterans, the uninsured or Medicaid recipients—have their health coverage at least partially subsidized by taxpayers. ...

4 of the top 10 highest paid CEOs are in Medical Supplies or Drugs.

Hosea 6:8:  

"Gilead is a city of those who work iniquity; it is stained with blood."


 The Republican Healthcare Plan is the same as the Nazi Healthcare Plan for Old Jews...



Britain Says #Gilead #Science #Sovaldi Drug Too Expensive to Pay $84,000 for drug that costs $67 to make.

Britain's cost agency not ready to back Gilead hepatitis C drug

LONDON Mon Jun 16, 2014 12:59pm EDT

The National Institute for Health and Care Excellence (NICE) said it was "minded not to recommend" the drug, which is also known as sofosbuvir. The decision poses a hurdle to its widespread adoption in Britain. ...

UK gatekeepers nix hep C drug Sovaldi till Gilead ponies up more evidence

FiercePharma - ‎3 hours ago‎
Should the British health service pay for the expensive-yet-effective hepatitis C treatment Sovaldi? The U.K.'s cost-effectiveness gatekeepers say they're not convinced. With an $84,000 price tag in the U.S., Sovaldi has touched off a vociferous debate about ...


"The available evidence shows that sofosbuvir is an effective treatment for chronic hepatitis C in certain patients," Carole Longson, director of NICE's health evaluation center, said in a statement. "However, evidence is lacking for some subgroups of patients with chronic hepatitis C, and there are also substantial uncertainties in the evidence base presented by the manufacturer."

It's an early guidance, with final word expected in October. In the realm of NICE's "not minded to" decisions, it's fairly positive. Chances are that Gilead ($GILD) can sway the outcome with additional evidence and number-crunching. But NICE's evaluation could spur price negotiations; often, the agency presses drugmakers for discounts or other cost-cutting schemes, and successfully. Already, Gilead has priced Sovaldi much lower in the U.K. than in the U.S., at about $57,000.

UK Cost Regulator May Reject Gilead's Sovaldi Treatment

Businessweek - ‎8 hours ago‎
The U.K.'s health-cost regulator said it may reject Gilead Sciences Inc. (GILD:US)'s $60,000 hepatitis C drug Sovaldi, and asked for more data before deciding whether the British government should pay for the treatment. Gilead lacks evidence on Sovaldi for ...

Sunday, June 15, 2014

#Liber8 #Gilead Sciences CEO Martin : $180 Million Man

Gilead Sciences CEO Martin : $180 Million Man

... "In what's shaping up as a year of oversized paydays for chief executives, Gilead Sciences CEO John Martin has emerged as one of 2013's biggest winners.

Martin pulled in compensation valued at nearly $180 million in 2013, including stock option gains worth $158 million, the biotech giant said Friday. Martin received $15.4 million in salary, incentive awards, stock and stock options -- about what he's made in each of the past three fiscal years. But he cashed in on stock options for a $158.9 million gain and received another $4.8 million from shares that vested last year, Gilead said in a preliminary proxy filing.
Martin's overall compensation was nearly double the $95.8 million he received in 2012, including $80.5 million from vested shares and stock option gains. He received about $54.5 million in 2011 compensation and $53.2 million in 2010, according to company filings."



Saturday, June 14, 2014

Gilead: This Drug Costs $84,000 in the U.S., but Just $900 Elsewhere

... "That might have something to do with a recent deal Gilead cut with the government of Egypt to provide the hepatitis C treatment in government clinics at a 99 percent discount. Where it will cost American patients $84,000, it will cost Egyptians just $900 for the full 12-week treatment." ...

That is VERY misleading. Egypt GOVERNMENT is getting a $900 per cure price, but if you are not on the govt best friends list you have to pay $5,600 to your private doctor. Since the total number of Hep-C infections in Egypt is greater than the national health budget, most people will not get helped through the govt. The vast lot of poor people are just as much out of reach from the cure as Americans are out of reach of $84.000. Keep in mind that Gilead pays $2 per gram to make the drug, and the 84-day cure takes about 34 grams, so the manufacturing costs are $67 to make each bottle that sells for $900 in Egypt and sells for $84,000 for the exact same thing to American suckers.

Gilead, Tamiflu, George Schultz, Donald Rumsfeld, George W. Bush

Through the Looking Glass Darkly

Government as we wish it or government as we will it
... President George W. Bush sought to instill panic in the United States by telling us that a minimum of 200,000 people would die from the avian flu pandemic. But it could be as bad as 2 million deaths in this country alone, we were told.

This hoax was then used to justify the immediate purchase of 20 million doses of Tamiflu, at $100 per dose, for a total of $2 billion. Tamiflu is a drug of little known value in treating the disease and can actually contribute to the virus having more lethal mutations.8 Coincidentally or not, Donald Rumsfeld, George W. Bush’s Secretary of defense, was appointed Chairman of Gilead Sciences, Inc. in 1997, the company that developed the Tamiflu. He [Rumsfeld], the largest Gilead stockholder, was in a position to make a fortune on royalties, as the value of a share soared 700% in just a few weeks. In October 2005, the Pentagon ordered vaccination of all US military personnel worldwide against this same Avian Flu.
 Then, in 2009, along came the swine flu pandemic scare, same cast of characters, same drug, same attempts at forced inoculation to the benefit of the drug companies. In this case, the disease itself seems to have been created in a laboratory, which makes sense. Create the disease, create the scare, force inoculation, “for your own good,” reap the profits. ...

Gilead Sciences, Inc. past relationships:

People related to Gilead Sciences, Inc.:

Muckety Gilead -- "Gilead is a city of those who work iniquity; it is stained with blood."

Gilead Sciences, Inc.

Address: Foster City, CA

Business sector: 
biological products

People related to Gilead Sciences, Inc.:

Other current Gilead Sciences, Inc. relationships:

Gilead Sciences, Inc. past relationships:

John C. Martin, PhD  
Chairman and Chief Executive Officer

John F. Milligan, PhD  
President and Chief Operating Officer

Norbert W. Bischofberger, PhD  
Executive Vice President, Research and Development and Chief Scientific Officer

Robin L. Washington  
Executive Vice President and Chief Financial Officer

Gregg H. Alton  
Executive Vice President, Corporate and Medical Affairs

Paul R. Carter  
Executive Vice President, Commercial Operations

John McHutchison, MD  
Executive Vice President, Clinical Research

Katie L. Watson  
Senior Vice President, Human Resources

Per Wold-Olsen

Age in 2014: 66

Areas of interest:
biological products industry
pharmaceuticals industry
Personal social network: Much of Wold-Olsen's Muckety comes from business connections.  

Per Wold-Olsen current relationships:

Per Wold-Olsen past relationships:

Barron's ‎- 3 days ago
Gilead investors shouldn't overreact to Merck's $3.8 billion purchase of Idenix and its Hepatitis C portfolio.

With GILEAD setting the price of $1,000 a day for 84-day treatment, the competition is not forcing the price low, but pushing it higher.


 The Republican Healthcare Plan is the same as the Nazi Healthcare Plan for Old Jews...

... in fact, with 300,000,000 poor people infected with Hepatitis-C worldwide, Gilead will participate in killing more people than Hitler's SS ever dreamed of.

It costs $2 per gram to make Gilead's wonder drug, and one gram is two and a half day's supply. It costs less than $80 to make this $84,000 treatment.

Friday, June 13, 2014

Continuum Drug Company Villains: Sonmanto, Fermitas, Gautuma, Gilead

Season 3 - Episode 8

So Do Our Minutes Hasten

In the present, Inspector Dillon squares off with Julian on Diana Bolton's news show. Dillon defends PIRON's extensive investment into the VPD while Julian claims that it's another step closer to a totalitarian police-state. ...

At a Fermitas board meeting, toxic gas pours in from the vents. The executives are trapped when the board room doors electronic locks fail to release. They are killed within minutes. ...

Season 3 - Episode 6

Wasted Minutes
At Sonmanto's headquarters, Gord Solomon (Liber8's "lawyer") announces to a throng of press that not only did Sonmanto know about the ability to weaponize their chemicals, they've already begun profiting from that knowledge. In a rage, Kiera detains Solomon in front of the media crowd. Tearfully, she confesses to Carlos her betrayed realization: Sonmanto didn't just make the antidote in the future - they also manufactured the toxin that killed people she knew and nearly killed her. ...

Revolutions Per Minute is the tenth episode of Season 3, and the 33rd episode overall, of Continuum.

Meanwhile, Carlos and Kiera work together to anticipate Liber8's next target. They narrow the corporations down to Gautuma Medical, a relatively small pharmaceutical company that balloons into a big pharmacy behemoth in her future. The detectives meet with an executive at Gautuma who provides some insight on their current promising research into a cure for Alzheimer's. Unbeknownst to them, Christine has been planted as a janitor there by Liber8. She calls Lucas, alerting them to their surprise presence.  ...

Hosea 6:8:  

"Gilead is a city of those who work iniquity; it is stained with blood."

New Treatments for Hepatitis C Virus: Strategies for Achieving Universal Access

New Treatments for Hepatitis C Virus: Strategies for Achieving Universal Access

New Treatments for Hepatitis C Virus: Strategies for ...
Mar 19, 2014 - New Treatments for Hepatitis C Virus: Strategies for Achieving Universal Access. By Pauline Londeix, technical advisor to M├ędecins du Monde, ...

Download the Full Report here - ITPC-MENA
by P Londeix - ‎2014
Mar 4, 2014 - Strategies for Achieving. Universal Access .... pharmaceutical companies, universal access would be prac- tically unachievable, even in .... expanding access to new HCV treatments, and compares them in order to determine ...

Why Merck Just Spent $4 Billion On New Drugs For Hepatitis C

Forbes - ‎Jun 9, 2014‎
Wall Street has already declared a winner in the race to develop new treatments for hepatitis C, a virus that infects 3.2 million Americans that is the leading cause of liver transplantation in the United States. It's Gilead Sciences. Everyone knows that Gilead's Sovaldi, already the best drug ... It's just impossible.” Gilead hopes to launch a three-drug, one-pill hepatitis C treatment this fall, and is expected to mop up a huge number of hepatitis C patients. Already, Sovaldi's rapid uptake in usage has led to protests from ... 

Merck & Co to buy Idenix to boost hepatitis C drugs portfolio

Reuters - ‎Jun 9, 2014‎
The payoff for Merck could come from a triple therapy that may cure patients with all genotypes, or strains, of the hepatitis C virus in as little as four to six weeks, its research chief, Roger Perlmutter, said in an interview. "An ideal therapy ... In a recent mid-stage trial, Merck's two-drug combo cured 98 percent of previously untreated patients with genotype 1, the most common and hardest to treat variant of hepatitis C. The Idenix drug in .... Bankruptcy Law · California Legal · New York Legal · Securities Law. Support & ...

Merck & Co. to Buy Hepatitis-Drug Maker Idenix

Bloomberg - ‎Jun 9, 2014‎
Buying the Cambridge, Massachusetts-based company will help Merck in the competition to develop a daily, all-oral regimen that treats different strains of the viral infection and doesn't include ribavirin, a standard therapy for hepatitis C that has serious side effects. In April, Merck said its once-a-day hepatitis C pill, which combined two drugs, stopped ... Merck shares gained less than 1 percent to $57.94 at the close in New York. Idenix shares more than tripled to $23.79. Idenix came to Merck after another company ...

Merck Bids $3.8 Billion for an Edge in Hepatitis

New York Times - ‎Jun 9, 2014‎
New drugs are transforming the treatment of hepatitis C, replacing injections with pills, as well as increasing the cure rates, reducing side effects and cutting the duration of treatment to as little as eight to 12 weeks from as long as a year. But the new pills for ... to 18 weeks of treatment. Adding a drug from Idenix to those two drugs could allow for a once-a-day pill that could treat all subtypes of the virus in as little as four weeks, Dr. Roger Perlmutter, who heads research and development for Merck, said in an interview.

Merck to buy Idenix for $3.9 billion for Hepatitis C - ‎Jun 9, 2014‎
based company will help Merck in the race to develop a daily, all-oral regimen that treats different strains of the viral infection and doesn't include ribavirin, a standard treatment for hepatitis C that has serious side effects. In April, Merck ... "The big pharma companies understand that the prevalence of people with hep-C is so big that the market is going to be around for the next 10 years," said Jason Kolbert, senior managing director with Maxim Group LLC in New York, in a telephone interview Monday. "It's a very fair ...

Merck agrees to buy Idenix for $3.85 billion

USA TODAY - ‎Jun 9, 2014‎
Drug companies are racing to test new and potentially lucrative treatments for hepatitis C. An estimated 3 million people in the USA are chronically infected with hepatitis C, the nation's leading cause of liver cancer and liver transplants. About half or more of ... It has three drugs in clinical development to treat the hepatitis C virus, known as HCV. Merck's ... The addition of the Idenix portfolio to our breakthrough treatments already under development brings us one step closer to achieving this goal." The Centers for ...

Merck to buy hepatitis C treatment maker Idenix Pharma

The Globe and Mail - ‎Jun 9, 2014‎
based Idenix – seems high. However, the latest hepatitis C medicines command very high prices, the number of patients keeps rising and Merck was bidding against rivals. Hepatitis C has become one of the hottest categories in drug research as companies ...

Merck to Pay $3.85B for Hepatitis C Drug Developer

ABC News - ‎Jun 9, 2014‎
Hepatitis C has become one of the hottest categories in drug research as companies race to develop a combination therapy without injections and debilitating side effects. Some have had their promising candidates fail after extensive testing, due to dangerous side effects, but Gilead Sciences Inc. ... Three Idenix experimental drugs have reached human testing and one, samatasvir, is in mid-stage testing. It's in a new drug class called NS5A inhibitors, which disrupt various stages of the virus life cycle. Two other drugs ...

UPDATED: Merck scoops up troubled Idenix's hep C drugs in $3.85B buyout

FierceBiotech - ‎Jun 9, 2014‎
Eight months after it promised to go on a shopping spree for new experimental drugs, Merck ($MRK) has come up with a $3.85 billion cash deal to buy out Idenix, a biotech company best known for its setbacks in hepatitis C drug research. The deal instantly broadens Merck's ... Hepatitis C was once one of the hottest fields in biotech for M&A, but the deal-making cooled dramatically over the past two years as Gilead surged forward and other companies experienced setbacks. This morning, though, the focus is back on ...

Merck to buy Cambridge's Idenix in $3.85b deal

Boston Globe - ‎Jun 10, 2014‎
The pharmaceutical giant Merck & Co. agreed on Monday to pay $3.85 billion for a Cambridge biotech that is developing drugs to cure hepatitis C, a staggering price for a small company with fewer than 100 employees. Merck's agreement to buy 16-year-old Idenix Pharmaceuticals Inc. is the latest sign the Boston-area biotechnology cluster has become a powerful magnet for global drug makers in search of breakthrough medicines — and huge profits. Continue reading .... 1/28/14: Abby fight may be with mediocrity.

Investors eye Achillion for next big pharma deal - ‎Jun 11, 2014‎
While AbbVie, Bristol-Myers and J&J are in the race with Merck and Gilead to develop new treatments for hepatitis C, a market estimated to be worth more than $20 billion in 2018, those three companies are left without nucs, Bayko noted. Nucs are considered to be a key ... $1B profit on Idenix deal. The goal among drugmakers now is to develop a single pill that patients can take once a day, with fewer side effects, that will cure the virus for all patients in the shortest period of time—potentially in a matter of weeks.

4 of the top 10 highest paid CEOs are in Medical Supplies or Drugs.

Catching Hepatitis: Why Merck (MRK) Was Willing to Break the Bank for Idenix (IDIX) 

Sovaldi Has Demonstrated Treating Hepatitis C is a Good Business to Be In

Idenix has zero, count ‘em, zero therapies that are currently commercially available and had zero, count ‘em, zero dollars in revenue last year. So why the massive price tag for a company whose most-advanced therapy has only reached Phase II clinical trials? Because the company’s primary focus is treating hepatitis C, a market that has grown astonishingly lucrative and is getting astonishingly competitive as a result. ISI Group analyst Mark Schoenebaum said in a research note the price paid by Merck would place the global hepatitis C market at $20 billion by 2018, and everyone's now fighting to secure their piece.
The first inklings that this would be the case came when Gilead Sciences (GILD) announced that Sovaldi, the first truly effective hepatitis C treatment to hit the market, would cost $84,000 for a round of treatment, better than $1,000 a pill.
This created waves. Big ones. Henry Waxman fired off a strongly-worded letter to Gilead CEO Dr. John C. Martin ...


Click photos for larger size

 John C. Martin, Gilead Sciences #10 recently moved to #1 

 Stephen Hemsley, United Health Group

 John Hammergreen, McKesson Medical Supplies

John Hammergreen, McKesson Medical Supplies


VA puts Gilead's $1,000-a-pill hepatitis C drug on its list of meds


Activists pounce on $1,000-a-day price for Gilead's hep C wonder drug, Sovaldi


Is this Gilead's Biggest Risk?

Motley Fool - ‎22 minutes ago‎
In fact, Sovaldi poses a huge riddle for Gilead. How can a $1,000 pill designed overwhelmingly for those who are low-income, or live in low- income countries, become accessible to the patients who need it most? In the United States, more than half of the ... In the near term, Gilead faces a risk doctors may choose to wait to treat hepatitis C patients until later in 2014, when the fixed-dose combination Sovaldi + Ledipasvir becomes available. At the very least, the need to find all those new patients each quarter will make ... 

AHF Supports AHIP's Labeling of Sovaldi Pricing as “Unsustainable,” Reaffirms ...

MarketWatch - ‎Jun 12, 2014‎
WASHINGTON, Jun 12, 2014 (BUSINESS WIRE) -- In a series of letters to be sent to state Medicaid directors this week, AIDS Healthcare Foundation (AHF) President Michael Weinstein will ask the state directors to block Gilead Sciences' new $1,000-per-pill ... 

Govt urged to make new hepatitis drug affordable - ‎20 hours ago‎
Sovaldi, whose developer, Gilead, an American pharmaceutical company, is expected to earn $9.1 billion by 2017, was recently registered by the US Food and Drug Administration. However, it has yet to be registered in Pakistan. ... According to Professor Najib, the cost of Sovadi is $1,000 per tablet in the US and that the high price forced local insurance companies to have reservations about its coverage in the health insurance schemes and thus, restricting its prescription. “Unfortunately, the laws of the potency of ...

Health: No sofosbuvir patent in Egypt, but Gilead deal still expensive
Cairo, 8 April (Heba Wanis*) – Preliminary examination of the patent application on sofosbuvir, a major hepatitis C medicine, at the Egyptian Patent Office showed that it is unlikely to be patented. 

India’s pro-consumer patent regime is an exciting alternative to the dominant IP model pushed by the US

Gilead’s Sovaldi is a wonder drug sold at a shocker price. It is the most effective cure for Hepatitis C, and is in high demand. But the drug has caused an outrage in the US where patients, healthcare providers and insurers have questioned its exorbitant price tag. For a 12-week course, Sovaldi costs $84,000 (₹50,00,000). 

Sovaldi was also in the news for an entirely different set of reasons. Earlier this month, an Indian generic firm, Natco, filed a ‘pre-grant opposition’ to Gilead’s patent covering Sovaldi. The move could result in the Indian Patent Office rejecting Gilead’s patent, bringing down the price to a fraction of its current price.

This is not a one-off incident. India has tackled the issue of unaffordable prices of drugs protected by patents by incorporating a remarkable array of provisions into its intellectual property (IP) law. 

These provisions qualify as ‘legitimate flexibilities’ allowed under the WTO’s Trade Related aspects of Intellectual Property Rights (TRIPS) Agreement. ...

At $1000 per pill, Gilead's hepatitis C drug has insurers, others ...

San Francisco Business Times (blog)-May 30, 2014
Drug manufacturer Gilead Sciences defends the price tag on grounds ... over a 10-to-30-year span, leading to cirrhosis, liver failure and death. ...

Hepatitis C drugs show promise, but price is too high for most patients

CTV News-May 25, 2014
In an email to CTV News, Gilead, the makers of Sovaldi, said that the ... sugar-coat her reality: "I am stage 4, the next step is death," she said. you know there is a cure for Hepatitis C but we may never see it?
  • Over 170 million people worldwide have the virus, 4 million people in the U.S.
  • Hepatitis C (HCV) now kills more people than AIDS
  • Liver Cancer due to Hepatitis C is the most rapidly increasing cause of cancer death in the U.S.
  • HCV is the number one reason for liver transplants
  • 3-4% of adults are chronically infected
What can you do to help?
Act NOW and sign the petition to pressure Gilead Sciences to work with Bristol-Myers on the Phase III drug trials necessary to get the cure to market.

1980 Forest View Avenue
    Hillsborough, CA 94010
Find on map >>
Show street view
Land value: $1,671,831
Building value: $1,671,831
Total value for property: $3,343,662
Assessments for tax year: 2009
Last sale: $2,650,000
Date of last sale: 06/13/1997

  1. Rosemary Martin - $7,600 in Political Contributions for 2004
    HILLSBOROUGH, CA 94010, None/None, $5,000, 07/12/2004, P, GILEAD SCIENCES INC HEALTHCARE POLICY PAC · Martin, Rosemary A Mrs. PEARLAND ...
  2. Rosemary Martin - $5,000 in Political Contributions for 2006
    ... Contibuted To. Martin, Rosemary HILLSBOROUGH, CA 94010, Homemaker, $5,000, 01/11/2006, P, GILEAD SCIENCES INC HEALTHCARE POLICY PAC ...
  3. HILLSBOROUGH, California (CA) Political Contributions by ...
    Latest news about elections in HILLSBOROUGH, CA collected exclusively by ...... Rosemary Martin (Homemaker), (Zip code: 94010) $5000 to GILEAD ...
  4. HILLSBOROUGH, California (CA) Political Contributions by ...
    FCC Registered Amateur Radio Licenses in city_name, California. ... Rosemary Martin (None/None), (Zip code: 94010) $5000 to GILEAD SCIENCES INC ...
  5. **Obituaries** - Florida Times-Union
    The Florida Times‑Union
    Nov 21, 2000 - She is survived by her husband, Dr. Tellis A. Martin; four children; Dr. John C. (Rosemary) Martin of Hillsborough, CA, Carolyn L. (Thomas) ...

    MARTIN - Janet Sacks Martin, 72, passed away on Saturday, November 18, 2000. She was born on January 11, 1928 in Philadelphia, PA. She graduated from Ursinus College in Collegeville, PA with a B. S. in Chemistry in 1949. Jan moved with her family to Evansville, Indiana in 1953. After graduating from the University of Evansville with a Masters in Education, she taught chemistry, physics and computer literacy at the Evansville Day School for move than twenty years. She relocated to Isle of Palms, SC after retirement in 1987 where she was an elder of the Sunrise Presbyterian Church, and active in the Garden Club, the Newcomers Club, the Literacy Program of Charleston and was a volunteer Medicare claims filer. In 1996 she moved to Penny Retirement Community in Penny Farms, FL, but continued to Summer in Isle of Palms. At PRC, she was Treasurer of the PRC Association and a volunteer AARP tax preparer. Jan will be remembered as a loving daughter, wife, mother and grandmother, an excellent bridge player and a good and generous friend to many. She is survived by her husband, Dr. Tellis A. Martin; four children; Dr. John C. (Rosemary) Martin of Hillsborough, CA, Carolyn L. (Thomas) Marino of New York City, Dr. Robert Sacks (Rebecca) Martin of Pacific Palisades, CA and Thomas E. (Sue Ann) Martin, CPA of Concord, NJ; and seven grandchildren, John, Margaret Rose, Noah, Rachel, Chelsea, Kelly and Robert. A Graveside memorial service will be held at 10:'30 Am on Saturday, December 2, at Penny Farms Cemetery. Memorial donations in Janets memory may be made to Penny Retirement Community, Janet Martin Memorial Fund, Box 555, Penny Farms, FL 32079.

Sue Ann Martin

John C. Martin, Ph.D., joined Gilead Sciences in 1990 and currently serves as chairman of the board of directors and CEO. Prior to joining Gilead, Martin held several leadership positions at Bristol-Myers Squibb and Syntex Corp.
Martin has served as president of the International Society for Antiviral Research, chairman of the board of directors of BayBio and chairman of the California Healthcare Institute. He also served on the National Institute of Allergy & Infectious Diseases Council, on the board of directors of the Biotechnology Industry Organization (BIO), on the board of trustees of the University of Chicago and on the board of trustees of the Golden Gate University. Additionally, Martin served on the Centers for Disease Control/Health Resources and Services Administrations Advisory Committee on HIV and STD Prevention and Treatment and was a member of the Presidential Advisory Council on HIV/AIDS. He is currently a member of the board at Gen-Probe Inc. He has been a member of the board of directors of CHI since 2003 and previously served as chairman of the board from 2005 to 2006 and 2009.

Hosea 6:8:  

"Gilead is a city of those who work iniquity; it is stained with blood."

Current Addresss:
Current Phone:
Possible Relatives
Thomas Martin in Concord, NH
 Current Phone:
Current Phone:
  • John C. Martin, PhD

    Chairman and Chief Executive Officer, Gilead Sciences
  • John F. Cogan, PhD

    Lead Independent Director, Gilead Sciences
  • Etienne F. Davignon

    Minister of State for Belgium, Chairman, Genfina
  • Carla A. Hills

    Chair and Chief Executive Officer, Hills & Company, International Consultants
  • Kevin E. Lofton

    President and Chief Executive Officer, Catholic Health Initiatives
  • John W. Madigan

    Retired Chairman and Chief Executive Officer, Tribune Company
  • Nicholas G. Moore

    Retired Global Chairman, PricewaterhouseCoopers
  • George P. Shultz, PhD

    Director Emeritus, Gilead Sciences
  • Richard J. Whitley, MD

    Distinguished Professor, Loeb Scholar Chair in Pediatrics, Professor of Pediatrics, Microbiology, Medicine, and Neurosurgery, University of Alabama at Birmingham
  • Gayle Edlund Wilson

    Immediate Past Chair, Ralph M. Parsons Foundation
  • Per Wold-Olsen

    Retired President, Human Health Intercontinental Division, Merck & Co., Inc.